Kras G12C– and G12D–driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models
- DOI
- 10.1126/scitranslmed.adq6647
- Published
- 2026-02-04
- Container
- Science Translational Medicine
- Publisher
- American Association for the Advancement of Science (AAAS)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1126/scitranslmed.adq6647,
title = {Kras G12C– and G12D–driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models},
author = {Hai-Cheng Huang and Qing Deng and Lei Guo and Teresa Gorria and Federica Pecci and Daniella Yang and Scott Rodig and Luis De Las Casas and Jill Hallin and James G. Christensen and Mark M. Awad and Lin Xu and Biagio Ricciuti and Esra A. Akbay},
year = {2026},
journal = {Science Translational Medicine},
doi = {10.1126/scitranslmed.adq6647},
url = {https://doi.org/10.1126/scitranslmed.adq6647}
}RIS
TY - JOUR TI - Kras G12C– and G12D–driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models AU - Hai-Cheng Huang AU - Qing Deng AU - Lei Guo AU - Teresa Gorria AU - Federica Pecci AU - Daniella Yang AU - Scott Rodig AU - Luis De Las Casas AU - Jill Hallin AU - James G. Christensen AU - Mark M. Awad AU - Lin Xu AU - Biagio Ricciuti AU - Esra A. Akbay PY - 2026 JO - Science Translational Medicine DO - 10.1126/scitranslmed.adq6647 UR - https://doi.org/10.1126/scitranslmed.adq6647 ER -
APA
Huang, H., Deng, Q., Guo, L., Gorria, T., Pecci, F., Yang, D., Rodig, S., Casas, L. D. L., Hallin, J., Christensen, J. G., Awad, M. M., Xu, L., Ricciuti, B., & Akbay, E. A. (2026). Kras G12C– and G12D–driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adq6647
Source records
- crossref · retrieved 2026-09-26T21:49:15.412Z